Jillian Jacobson

Dr. Jillian Jacobson

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Children
Verified
Journal Article
Open access
PDF file
JJJillian Jacobson
Jillian Jacobson
RCRachael Clark
Rachael Clark
Dai ChungDai Chung
Dai Chung
High-risk neuroblastoma requires multimodal treatment including systemic chemotherapy, surgical resection, radiation therapy, stem cell transplant, and immunotherapy. Surgeons play a vital role in obtaining local control of neuroblastoma and must therefore be knowledgeable about this complex pathology. This article provides a review of the optimal timing and extent of resection, the impact of various image-defined risk factors on surgical planning, and surgical approaches and techniques to enhance the resection of tumors in different anatomic locations.

10 January 2022 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
RCRachael A Clark
Rachael A Clark
JJJillian Jacobson
Jillian Jacobson
ASAmogh Bs Singhal
Amogh Bs Singhal
AAAdam C Md Alder
Adam C Md Alder
Dai ChungDai Chung
Dai Chung
SPSamir R Md Pandya
Samir R Md Pandya
Export BACKGROUND: Minimally invasive repair of pectus excavatum (MIRPE) involves placement of a transthoracic, retrosternal support bar under thoracoscopic guidance. Despite its minimally invasive technical approach, postoperative pain is a significant morbidity that often results in increased length of stay. Multi-modal pain control strategies have been used in the past with limited success. Recently, the use of intraoperative intercostal nerve cryoablation (CA) has been added. In the present study, we aim to evaluate the effects of CA on postoperative pain control, opioid requirements, and perioperative outcomes. STUDY DESIGN: A single-center, retrospective chart review of all patients (less than 18 years old) who underwent MIRPE from 2009 to 2020 was performed. CA was started in June 2018. Data collection included demographics, preoperative characteristics, intraoperative findings, and postoperative outcomes. We hypothesized that CA would be associated with improved pain scores, lower doses of total inpatient opioid requirement, and shorter length of stay (LOS). RESULTS: One hundred sixty-one patients met inclusion criteria: 75 underwent intraoperative CA and 86 underwent MIRPE without CA (NCA group). CA significantly decreased median LOS from 4 days in NCA to 2 days; the use of CA was the only significant predictor of LOS on linear regression. CA was also associated with decreased total PCA, intravenous opioid, and oral opioid dosages. There was no difference in inpatient pain scores and a slight increase in mean procedure time. However, CA was associated with significantly decreased postoperative complications. CONCLUSIONS: The use of cryoablation during MIRPE significantly decreases LOS, perioperative opioid requirements, and postoperative complications, with a minimal increase in operative time. Cryoablation is an effective pain control modality in the surgical management of chest wall deformities in children.

16 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JQJingbo Qiao
Jingbo Qiao
JLJunquan Liu
Junquan Liu
JJJillian Jacobson
Jillian Jacobson
RCRachael A. Clark
Rachael A. Clark
SLSora Lee
Sora Lee
Dai ChungDai Chung
Dai Chung
Standard treatment for patients with high-risk neuroblastoma remains multimodal therapy including chemoradiation, surgical resection, and autologous stem cell rescue. Immunotherapy has demonstrated success in treating many types of cancers; however, its use in pediatric solid tumors has been limited by low tumor mutation burdens. Gastrin-releasing peptide receptor (GRP-R) is overexpressed in numerous malignancies, including poorly-differentiated neuroblastoma. Monoclonal antibodies (mAbs) to GRP-R have yet to be developed but could serve as a potential novel immunotherapy. This preclinical study aims to evaluate the efficacy of a novel GRP-R mAb immunotherapy against neuroblastoma. We established four candidate anti-GRP-R mAbs by screening a single-chain variable fragment (scFv) library. GRP-R mAb-1 demonstrated the highest efficacy with the lowest EC50 at 4.607 ng/ml against GRP-R expressing neuroblastoma cells, blocked the GRP-ligand activation of GRP-R and its downstream PI3K/AKT signaling. This resulted in functional inhibition of cell proliferation and anchorage-independent growth, indicating that mAb-1 has an antagonist inhibitory role on GRP-R. To examine the antibody-dependent cellular cytotoxicity (ADCC) of GRP-R mAb-1 on neuroblastoma, we co-cultured neuroblastoma cells with natural killer (NK) cells versus GRP-R mAb-1 treatment alone. GRP-R mAb-1 mediated ADCC effects on neuroblastoma cells and induced release of IFNγ by NK cells under co-culture conditions in vitro. The cytotoxic effects of mAb-1 were confirmed with the secretion of cytotoxic granzyme B from NK cells and the reduction of mitotic tumor cells in vivo using a murine tumor xenograft model. In summary, GRP-R mAb-1 demonstrated efficacious anti-tumor effects on neuroblastoma cells in preclinical models. Importantly, GRP-R mAb-1 may be an efficacious, novel immunotherapy in the treatment of high-risk neuroblastoma patients.

1 July 2022 in Journal of Laparoendoscopic & Advanced Surgical Techniques
Verified
Journal Article
Closed access
JJJillian Jacobson
Jillian Jacobson
MBMaggie E. Bosley
Maggie E. Bosley
MGMichaela W. Gaffley
Michaela W. Gaffley
JDJames S. Davis
James S. Davis
LNLucas P. Neff
Lucas P. Neff
Introduction: Biliary dyskinesia is typically defined as a gallbladder ejection fraction (EF) <35% on hepatobiliary iminodiacetic acid scan with cholecystokinin stimulation (CCK-HIDA) testing. Cholecystectomy often leads to resolution of associated biliary colic symptoms. Alternatively, there is a subset of symptomatic patients with normal gallbladder EF on CCK-HIDA. It has been proposed that pain with CCK injection is more predictive of symptom resolution after cholecystectomy than low gallbladder EF. We reviewed our experience with pediatric patients with positive CCK provocation testing and a normal gallbladder EF in the absence of gallstones. Materials and Methods: We retrospectively reviewed the records of all pediatric patients with normal hepatobiliary iminodiacetic acid EFs (35%–80%) and pain with CCK injection at a tertiary care center between 2016 and 2020. Age, gender, body mass index (BMI), CCK-HIDA results, and pathology analysis were noted. Short- and long-term resolution of symptoms was determined by patient self-reporting at a mean of 3 weeks and 46 months, respectively. Results: Seventeen patients met inclusion criteria. Average age was 15.1 years (range, 12–17 years) with median BMI 24.9 (± 4.9 kg/m 2 ). Mean CCK-HIDA EF was 56.3% (± 11.4%). In total, 62.5% of patients had evidence of chronic cholecystitis and/or cholesterolosis on pathology analysis. Of patients available for short-term and long-term postoperative follow-up, 80% and 83% reported complete or near complete resolution of symptoms, respectively. Conclusions: Normokinetic biliary dyskinesia is poorly understood but appears to be associated with chronic inflammation and cured by surgical intervention. Laparoscopic cholecystectomy results in resolution of symptoms for a majority of patients and should be considered in those with pain with CCK injection despite normal imaging studies. Clinical Trial Registration Number: 1657640-2.

1 December 2020 in Journal of Surgical Research
Verified
Journal Article
Closed access
JJJillian Jacobson
Jillian Jacobson
HPHeather Postma
Heather Postma
AMAli Mokdad
Ali Mokdad
FQFaisal Qureshi
Faisal Qureshi
AAAdam Alder
Adam Alder
SPSamir Pandya
Samir Pandya

29 January 2025 in Children
Verified
Journal Article
Open access
PDF file
ECElizabeth Cochran
Elizabeth Cochran
JJJillian Jacobson
Jillian Jacobson
AMArti Machchhar
Arti Machchhar
JQJingbo Qiao
Jingbo Qiao
Dai ChungDai Chung
Dai Chung
Background: Perioperative blood transfusion has been identified as a risk factor for postoperative infectious complications in adult patients with cancer. This study aimed to determine whether this association also exists in pediatric patients with cancer. Methods: A retrospective analysis was performed using the American College of Surgeons National Surgical Quality Improvement Program Pediatric (NSQIP-P) database. Pediatric patients with an active cancer diagnosis at the time of surgical intervention from 2015 to 2019 were reviewed. Statistical analysis was performed using Pearson chi-square and Fisher’s exact tests as well as multiple logistic regression. Result: In total, 14,973 pediatric patients who underwent a surgical procedure and had an active cancer diagnosis at the time of operation were identified. Of these, 2602 patients (17.4%) received a perioperative blood transfusion (PBT). Patients who received a PBT experienced higher rates of postoperative infectious complications, including surgical-site infection (p < 0.0001), pneumonia (p < 0.0001), urinary tract infection (p < 0.0001), C. difficile infection (p < 0.0001), central-line-associated bloodstream infection (p < 0.0001), and sepsis (p < 0.0001). Patients who received a PBT also had increased 30-day mortality compared with those who did not receive a PBT (p < 0.0001). On multivariate analysis, PBT remained an independent risk factor for postoperative infectious complications (OR 1.9, 95% CI 1.61–2.32) and death (OR 1.8, 95% CI 1.23–2.71). Conclusions: Pediatric patients with cancer who undergo surgery and receive a blood transfusion in the perioperative period have increased 30-day mortality and are at increased risk for postoperative infectious complications. Considering that these patients are often immunosuppressed at baseline, infections can be particularly devastating in this population. As such, it is important to carefully consider the risks and benefits of PBT prior to transfusion.